tbuckley/cabot-search huggingface dataset:
GENE-33. INTEGRATED GLIOMA DIAGNOSTICS USING TARGETED NEXT-GENERATION SEQUENCING
Authors: Jeanette K Petersen, Henning B Boldt, Mia Sorensen, Rikke H Dahlrot, Steinbjørn Hansen, Mark Burton, Mads Thomassen, Torben Kruse, Frantz R Poulsen, Lotte Andreasen, Henrik Hager, Benedicte P Ulhøi, Slavka Lukacova, Guido Reifenberger, Bjarne Kristensen
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Targeted next-generation sequencing (NGS) offers promising diagnostic perspectives by making it possible to detect genetic alterations with high accuracy in multiple genes as part of the daily diagnostic work-up. The importance of genetic alterations is reflected in the 2016 WHO classification of CNS tumors, where specific alterations are incorporated in the definition of certain entities. The aim of this study was to assess the diagnostic potential of a customized targeted glioma-tailored 20-gene panel to identify molecular entities of gliomas and explore their distinct mutational profiles. Moreover, the prognostic impact of molecular diagnostics was explored. METHODS We used a setup with NGS, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on a series of 756 glioma from both a retro- and prospective cohort. NGS data were obtained for 347 gliomas (225 analyzed prospectively, 122 analyzed retrospectively). RESULTS Three major clusters were identified by unsupervised hierarchial cluster analysis: 1) isocitrate dehydrogenase gene (IDH) 1 or 2 mutant astrocytomas with frequent mutations in TP53 (83%) and ATRX (69%), 2) IDH-mutant and 1p/19q-codeleted oligodendrogliomas with frequent mutations in TERT (65%) and CIC (52%), and 3) IDH-wildtype astrocytic gliomas/glioblastomas with frequent mutations in TERT (32%), PTEN (28%) and TP53 (22%). Among the IHC IDH1-R132H negative gliomas, NGS detected other IDH mutations in 16% of the cases. Moreover, rare but diagnostically important mutations such as BRAF V600E and H3F3A K27M were detected. Survival analysis of the reclassified gliomas showed a clear difference in survival between patients with WHO 2007 and 2016 diagnoses. Successful prospective NGS analyses were obtained for 98% of the gliomas in daily diagnostics. CONCLUSION Application of NGS panel sequencing improves diagnostic accuracy and is feasible in daily diagnostics. NGS is ready to become part of standard diagnostics in the field of gliomas.
Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)
Authors: Elodie Bohers, Pierre-Julien Viailly, Philippe Ruminy, Vinciane Marchand, Mathieu Viennot, Victor Bobée, Vincent Delwail, Frederic Peyrade, Herve Maisonneuve, Julie Abraham, Catherine Thieblemont, Pierre Feugier, Gilles A. Salles, Fontanet Bijou, Gandhi Damaj, Gian-Matteo Pica, Peggy Dartigues-Cuillères, Philippe Gaulard, Jean-François Emile, Bettina Fabiani, Herve Tilly, Corinne Haioun, Steven Le Gouill, Rene-Olivier Casasnovas, Fabrice Jardin
Journal: Blood (2019)
Abstract 14669: Deep Thrombogenicity Phenotyping in Patients Undergoing WATCHMAN Left Atrial Appendage Occlusion
Authors: Matthew W Sherwood, Ganesh Venkataraman, Lenny ilkhanoff, Kevin Bliden, Udaya Tantry, Stanley Strickberger, Shahram Yazdan, Haroon Rashid, Robert McSwain, Andrea Fitzgerald, Paul A Gurbel
Journal: Circulation (2018)

Introduction: Although clinical trial data support left atrial appendage (LAA) occlusion, the optimal antithrombotic strategy following the procedure is untested and device-related thrombosis (DRT)...
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Authors: Amy Damask, P. Gabriel Steg, Gregory G. Schwartz, Michael Szarek, Emil Hagström, Lina Badimon, M. John Chapman, Catherine Boileau, Sotirios Tsimikas, Henry N. Ginsberg, Poulabi Banerjee, Garen Manvelian, Robert Pordy, Sibylle Hess, John D. Overton, Luca A. Lotta, George D. Yancopoulos, Goncalo R. Abecasis, Aris Baras, Charles Paulding
Journal: Circulation (2019)

Background: Alirocumab, an antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab). In this study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted greater benefit from alirocumab treatment. Recent studies indicate high polygenic risk scores (PRS) for coronary artery disease (CAD) identify individuals at higher risk who derive increased benefit from statins. We performed post hoc analyses to determine whether high PRS for CAD identifies higher-risk individuals, independent of baseline LDL-C and other known risk factors, who might derive greater benefit from alirocumab treatment. Methods: ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled trial comparing alirocumab or placebo in 18 924 patients with acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin treatment. The primary endpoint (MACE) comprised death of CAD, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization. A genome-wide PRS for CAD comprising 6 579 025 genetic variants was evaluated in 11 953 patients with available DNA samples. Analysis of MACE risk was performed in placebo-treated patients, whereas treatment benefit analysis was performed in all patients. Results: The incidence of MACE in the placebo group was related to PRS for CAD: 17.0% for high PRS patients (&gt;90th percentile) and 11.4% for lower PRS patients (≤90th percentile; P &lt;0.001); this PRS relationship was not explained by baseline LDL-C or other established risk factors. Both the absolute and relative reduction of MACE by alirocumab compared with placebo was greater in high versus low PRS patients. There was an absolute reduction by alirocumab in high versus low PRS groups of 6.0% and 1.5%, respectively, and a relative risk reduction by alirocumab of 37% in the high PRS group (hazard ratio, 0.63 [95% CI, 0.46–0.86]; P =0.004) versus a 13% reduction in the low PRS group (hazard ratio, 0.87 [95% CI, 0.78–0.98]; P =0.022; interaction P =0.04). Conclusions: A high PRS for CAD is associated with elevated risk for recurrent MACE after acute coronary syndrome and a larger absolute and relative risk reduction with alirocumab treatment, providing an independent tool for risk stratification and precision medicine.
The future of psychiatry
Authors: T Detre
Journal: American Journal of Psychiatry (1987)

The author reviews the vicissitudes of psychiatry's history over the past 50 years and urges the profession to abandon false boundaries between mind and brain and to make a commitment to the scientific validation of prevailing theories of the etiology of psychiatric disorders. He argues that the separation of psychiatry and neurology is no longer justified. He calls instead for a carefully conceived new career path leading to specialization in clinical neuroscience and further urges that psychiatric training programs be restructured to focus on the critical examination of problem solving and validation methods.
Testing for Coronary Microvascular Dysfunction
Authors: C. Noel Bairey Merz
Journal: JAMA (2019)

Testing for Coronary Microvascular DysfunctionCoronary microvascular dysfunction refers to abnormal dilation and constriction of the small blood vessels in the heart. What Is Coronary Microvascular Dysfunction?The small blood vessels in the heart, called the coronary microvasculature, carry most of the blood flow to the heart muscle, delivering oxygen.These blood vessels can become unhealthy when there is damage to their inner lining.There can also be plaque buildup in the larger coronary arteries that does not narrow them but can contribute to abnormal blood flow.Over time, this leads to abnormal widening or narrowing of the small vessels in response to exercise or stress, which can cause problems with the blood supply to the heart, causing chest pain, shortness of breath, heart attack, and heart failure.Conditions that increase a person's risk of having coronary microvascular dysfunction are high blood pressure (hypertension), diabetes, high cholesterol, smoking, autoimmune disease, and prior breast cancer treatment, as well as other unknown factors.Who Should Be Tested for Coronary Microvascular Dysfunction?
Recurrent Acute Idiopathic Thrombocytopenic Purpura
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Highly Robust Model for Predicting Outcome of Multiple Myeloma Patients By Inferring Patient-Specific Transcription Factor Activity
Authors: Chuanpeng Dong, Christina Y Yu, Travis S Johnson, Jill L Reiter, Mohammad Issam Abu Zaid, Rafat Abonour, G. David Roodman, Kun Huang, Yunlong Liu
Journal: Blood (2019)
Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment
Authors: Renato Torrescasana Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Eliseo J. Sekiya, Milton A. F. Aranha, Isabel Bonafe, Daniela Ferreira Dias, Adelson Alves
Journal: Blood (2019)
Telomere Length in Transfusion Dependent Thalassemia Patients
Authors: Nithita Nanthatanti, Adisak Tantiworawit, Nawapong Patpan, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada, Arintaya Phrommintikul, Wirote Tuntiwechapikul, Sirinart Kumfu, Nipon Chattipakorn
Journal: Blood (2016)
Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity
Authors: Alejandra Ortiz-Ruiz, Yanira Ruiz-Heredia, Mehmet Samur, Pedro Aguilar-Garrido, Maria Luz Morales, Antonio Valeri, Almudena Garcia-Ortiz, Santiago Barrio, Carmen Bárcena, Rosa Maria Garcia-Martin, Vanesa Garrido, Mariateresa Fulciniti, Nikhil C. Munshi, María Teresa Cedena, Joaquin Martinez-Lopez, Maria Linares, Miguel Gallardo
Journal: Blood (2019)
Outcome of Two Loci Mismatched (≤6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study
Authors: Arnon Nagler, Myriam Labopin, Benedetto Bruno, Alessandro Rambaldi, Pietro Pioltelli, Giorgio La Nasa, Gerard Socie, Stephan Mielke, Marco Ruggeri, Riccardo Saccardi, Uwe Platzbecker, Jürgen Finke, Annalisa Ruggeri, Bipin N. Savani, Mohamad Mohty
Journal: Blood (2019)
Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience
Authors: Banu Aygun, Nicole Mortier, Zora R. Rogers, William Owen, Beng Fuh, Alex George, Theodosia A. Kalfa, Janet Kwiatkowski, Margaret Lee, Hamayun Imran, Scott T. Miller, John C Wood, Alan R. Cohen, Sara L Pressel, Russell E. Ware
Journal: Blood (2016)
The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression
Authors: Costanza Zanetti, Joscha Ender, Mark Hartmann, Joschka Hey, Parimala Sonika Godavarthy, Eva Weissenberger, Rahul Kumar, Markus Metzler, Zhaohui Gu, Kathryn G. Roberts, Natalie Filmann, Clara D. Bloomfield, Wendy Stock, Charles G. Mullighan, Daniel B. Lipka, Daniela S. Krause
Journal: Blood (2019)
The Long Noncoding RNA BALR2 Controls Novel Transcriptional Circuits Involved in Chemotherapy Sensitivity of Pediatric Acute Myeloid Leukemia (AML) Blasts
Authors: Valeria Bisio, Maddalena Benetton, Elena Porcù, Matteo Bordi, Carlo Zanon, Giulia Borella, Ambra Da Ros, Giuseppe Germano, Sabrina Manni, Claudia Tregnago, Silvia Campello, Dinesh S. Rao, Franco Locatelli, Martina Pigazzi
Journal: Blood (2019)
GENE-53. IDENTIFICATION OF EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) AS A MOLECULAR MARKER AND THERAPEUTIC TARGET IN MENINGIOMA
Authors: Kunal Patel, Courtney Duong, Matthew Sun, Prasanth Romiyo, Sameer Kejriwal, Ann Chan, Lynn Gordon, Madhuri Wadehra, Isaac Yang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Intracranial meningiomas have been associated with a heterogenous set of genetic and molecular alterations. Despite these genetic associations, targeted therapies have been unable to increase survival in recurrent or residual meningiomas. There is a need for identification of therapeutic targets in meningioma. MATERIALS &amp; METHODS Normal brain tissue from routine autopsy and tumor specimens from patients undergoing primary surgical resection of meningioma were analyzed. Pathologic diagnosis and grade were identified. Samples were stained with anti-EMP2 antisera and visualized with DAB (3,3’-Diaminobenzidine). Western blot analysis was carried out RESULTS In 17 patients with meningioma, there was statistically significant EMP2 staining in fresh brain tumor samples. EMP2 expression was confirmed and quantified with western blot which demonstrated significant positive expressivity. There were 12 grade I, 4 grade II, and 1 grade III meningiomas in our dataset and a significant trend towards increased EMP2 expression with higher grade. EMP2 expression was not identified in normal brain tissue samples from different locations including gray matter, white matter, and meninges in 3 control patients. CONCLUSIONS EMP2 is a protein associated with cell migration, invasion, and angiogenesis not identified in normal brain tissue but found in meningioma. EMP2 expression may be associated with increased tumor invasion and is a potential therapeutic target for residual or recurrent meningioma.
Efficacy and Tolerability of High- vs Low-Volume Split-Dose Bowel Cleansing Regimens for Colonoscopy: A Systematic Review and Meta-analysis
Authors: Marco Spadaccini, Leonardo Frazzoni, Giuseppe Vanella, James East, Franco Radaelli, Cristiano Spada, Lorenzo Fuccio, Robert Benamouzig, Raf Bisschops, Michael Bretthauer, Evelien Dekker, Mario Dinis-Ribeiro, Monika Ferlitsch, Ian Gralnek, Rodrigo Jover, Michal F. Kaminski, Maria Pellisé, Konstantinos Triantafyllou, Jeanin E. Van Hooft, Jean-Marc Dumonceau, Clelia Marmo, Sergio Alfieri, Viveksandeep Thoguluva Chandrasekar, Prateek Sharma, Doug K. Rex, Alessandro Repici, Cesare Hassan
Journal: Clinical Gastroenterology and Hepatology (2019)
CMET-24. PLATEAU WAVE EVENTS: A COMMON, CURABLE, AND ROUTINELY MISDIAGNOSED SYNDROME IN PATIENTS WITH NEOPLASTIC MENINGITIS (NM)
Authors: Varun Padmanaban, Samer Zammar, Brad Zacharia, Elias Rizk, Sandra Ryan, Michael Glantz
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION NM is defined clinically by multilevel neurologic dysfunction. Seizures occur in less than 15% of patients. We describe a curable phenomenon (“plateau wave events”) that mimics and may be more common than seizures, but is not responsive to anticonvulsant medication. METHODS We queried a multinational NM registry to identify patients with episodic neurologic dysfunction suspected of having seizures. Detailed demographic, disease, treatment, and outcome data were collected. RESULTS Forty-three patients (21.2% of 203) were identified. Twenty patients (46.5% of 43) demonstrated a stereotyped constellation of symptoms including episodic severe headache and loss (19 patients) or impaired level (1 patient) of consciousness, nausea, vomiting, and gait instability lasting 30–180 seconds, with abrupt resolution and without post-ictal symptoms. Events developed a median of 74 (0–350) days following NM diagnosis. Fourteen patients (74%) were female. Median age was 54.8 [IQR 46.8, 61.6] years. Fourteen patients had solid tumors (11 breast), 5 had hematologic malignancies, and 1 had a primary brain tumor. Thirteen (68%) had ventriculomegaly. All patients demonstrated increased ICP [median 30.0 cm H2O, IQR 22.5, 30.0]. CSF cytology was positive and CSF protein was increased in 100% of patients, but no demographic, laboratory, or disease characteristic was associated with plateau wave events on multivariate analysis. Inter-ictal EEG in 8 patients showed no epileptiform activity. One intra-ictal EEG showed marked brainwave slowing and bradycardia during the clinical event. One intra-ictal ICP tracing showed an abrupt and dramatic increase in intracranial pressure during the event. Nineteen patients underwent ventriculoperitoneal shunting and experienced immediate symptom resolution. Anticonvulsant medication, initiated in 11 of these patients prior to shunting, provided no benefit. CONCLUSIONS Plateau wave events are common in patients with NM. They are frequently mistaken for seizures but are easily recognized by a constellation of defining signs and symptoms. Ventriculoperitoneal shunting is curative.
Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial
Authors: Josep-Maria Ribera, Olga García, Pilar Martinez, Pau Montesinos Fernandez, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, Natalia Alonso, José González-Campos, Arancha Bermúdez, Susana Vives, Mar Tormo, Jesús María Hernández-Rivas, Joaquin Martinez-Lopez, Ramón García-Sanz
Journal: Blood (2019)
Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib
Authors: Jonathan Kopel, Sriman Swarup, Anita Sultan, Lukman Tijani, Ei Moe Phyu, Myint Aung Win, Thura Win Htut, Ye Aung, Akshar Dash, Myat Min Han, Yin Mon Myat, Donald P. Quick, Nicholas D'Cunha, Kyaw Zin Thein
Journal: Blood (2019)
ACTR-51. REMARKABLE RESPONSE OF A PATIENT WITH SECONDARY GBM TO A HISTONE DEACETYLASE INHIBITOR
Authors: Hui-Kuo Shu, Saumya Gurbani, Karthik Ramesh, Brent Weinberg, Alfredo Voloschin, Jeffrey Olson, Hyunsuk Shim
Journal: Neuro-Oncology (2019)

Abstract Glioblastomas are highly aggressive, grade IV tumors of glial cells that arise either as de novo primary tumors or as secondary tumors, which malignantly transformed from lower grade gliomas. Secondary glioblastomas have a relatively low incidence making up 5–10% of all glioblastoma diagnoses and tend to occur in younger patients. However, these tumors are still quite aggressive with survival outcomes that do not differ substantially from primary glioblastomas. Secondary glioblastomas also often harbor mutation of isocitrate dehydrogenase (IDH) enzyme, which produces the oncometabolite 2-hydroxyglutarate (2-HG) from alpha-ketoglutarate (α-KG). The accumulation of 2-HG has several downstream effects due to its competitive inhibition of α-KG-dependent enzymes, including epigenetic modification via hypermethylation of histones. Histone deacetylase inhibitors (HDACi) are a class of molecules that inhibit histone deacetylation and have been shown to have anti-tumor effect in part due to this epigenetic modification. Thus, because of their shared targets with regard to histone modification, it is plausible that HDACi could counter the oncometabolite effects of accumulated 2-HG in IDH1 mutant tumors. Since belinostat is a pan-HDACi that has improved blood-brain barrier penetration compared to many other HDACis, we conducted a pilot study that enrolled 15 patients examining its upfront use for the treatment of glioblastomas and found that it was well tolerated. One patient in particular, likely with secondary glioblastoma harboring the typical IDH1 mutation, underwent treatment with standard chemoradiation as well as belinostat on this study. For this case, a remarkable improvement in tumor burden with very significant decrease in enhancing residual tumor and restoration of magnetic resonance spectroscopy (MRS)-detectable metabolism was noted. Furthermore, improved neurocognitition and quality-of-life were also observed in this patient during the 18-month follow-up period. Collectively, these outcomes potentially support the use of belinostat as an adjuvant therapy for patients with secondary glioblastoma that harbor a mutant IDH enzyme.
PDTM-25. STUDY OF ONC201 IN PRE-CLINICAL MODELS OF DIPG
Authors: Ajay Sharma, Yanlai Lai, Bridget Kennis, Sreepradha Sridharan, Tara Dobson, Jyothishmathi Swaminathan, Soumen Khatua, David Sandberg, Joshua Allen, Rohinton Tarapore, Vidya Gopalakrishnan, Wafik Zaky
Journal: Neuro-Oncology (2019)

Abstract Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable pediatric brain tumor that occur in the pons and brainstem and have a peak onset of age between 6–9 years of age. Radiation is currently used as standard of care. Chemotherapy has shown no improvements in survival. Here, we report our study of ONC201, a first-in-class anticancer small molecule developed by Oncoceutics, Inc., against DIPG cells in vitro and in mouse orthotopic models. ONC201 was discovered in a screen as a p53-independent inducer of the pro-apoptotic cytokine TRAIL. It is known to directly and selectively inhibit dopamine receptor D2 (DRD2), a member of the G protein-coupled receptor (GPCR) family. MTT assays to determine the sensitivity of DIPG cells to ONC201 revealed a slight but not significantly different response to the drug based on their expression of wild type (WT) histone H3 or histone H3K27M mutant protein, with IC50 values in the range of 3-8mM. Decrease in cell growth was associated with a decrease in AKT and ERK phosphorylation and an increase in TRAIL expression. In vivo, intraperitoneal administration of ONC201 to mice bearing pontine DIPG tumors, once every week for 6 weeks, caused a significant reduction in tumor burden relative to untreated controls as measured by bioluminescence assays. However, stoppage of treatment resulted in tumor regrowth within 6 weeks, suggesting the existence of a population that were not eliminated by the current schedule of ONC210. Single cell proteomic analyses-based comparison of untreated and ONC201-treated DIPG cells showed an expected global reduction in pro-survival signals such as phosphorylated AKT and ERK. Molecules with potential to predict susceptibility of cells to ONC201 were also revealed, and are being confirmed by transcriptome analyses. Results of a chemical screen to target ONC201-refractory tumor cells will be discussed.
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study
Authors: Annalisa Chiappella, Thomas E. Witzig, Kim Cocks, Mike Greenwood, Abi Williams, David W. Scott, Randy D. Gascoyne, Kazuhito Yamamoto, Wojciech Jurczak, Muhit Özcan, David Belada, Juan Miguel Bergua Burgues, Francesco Piazza, Carlo Visco, Gerardo Musuraca, Sandra Margunato-Debay, Myron Czuczman, Merry Zhai, Julia Braverman, Umberto Vitolo, Grzegorz Nowakowski
Journal: Blood (2019)